About
Dash Bio is a bioanalysis company founded in 2024 in Boston that applies automation and AI to accelerate drug development.
Technology & BusinessWhat · How · Which stage
Research Areas生命科学医药MediumEvidence
生物分析公司，利用自动化与 AI 加速药物开发
Source：Official site · Updated 2026-09-10 · View source
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2025-07New funding round$11M
Investors · Swift Ventures, Freestyle Capital, Drive Capital, Cybernetix Ventures, The Aligned Fund, LifeX VenturesSource · SVTR Weekly #115
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Dash Bio
Bioanalysis using automation and AI to accelerate drug development
Undisclosed · $11M · 2025-07
$11M
United States
BusinessLatest roundTotal raisedDate- Onepot
Small-molecule synthesis for drug discovery for biopharma companies (AI + automated synthesis)
Seed · $13M · 2025-11
$13M - Mithrl
Automated analysis of RNA sequencing data
Series A · $24M · 2026-09
$24M - Integrated Biosciences
Drugs for age-related diseases developed with synthetic biology and AI
Seed · $17M · 2024-10
$17M
China
BusinessLatest roundTotal raisedDate- 智源深澜
Developer of a generative AI platform for biomolecules
Angel · $22M · 2025-11
$22M - Coherence Biotech Co. Ltd.
Lab automation: the Keystone™ benchtop all-in-one system combines culturing, intervention and microscopy imaging into uninterrupted multi-day cell/organoid experiments and uses AI vision to identify, count and track cells, generating structured experimental data for AI drug discovery
— - MindRank
Designs and develops novel small-molecule drugs using its in-house AI drug discovery platform MAP
Series B · $52M · 2026-07
$52M
Europe
BusinessLatest roundTotal raisedDate- Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M - Bio Protocol
Funds and accelerates drug discovery through decentralized research agents
Seed · $7M · 2025-09
$7M - Helical
Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams
Seed · $20M · 2026-04
$20M
Other / unspecified
BusinessLatest roundTotal raisedDate- Mana.bio
Uses AI to design lipid nanoparticles for delivering mRNA to specific parts of the body
Seed · $20M · 2023-10
$20M - Halmos Labs
AI-driven automated R&D systems for biotech and pharma that simulate experimental outcomes before wet-lab work and recommend the experiments that most reduce uncertainty
— - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.